Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Leases: 2019-2025

Historic Current Leases for Ocular Therapeutix (OCUL) over the last 7 years, with Sep 2025 value amounting to $2.8 million.

  • Ocular Therapeutix's Current Leases rose 60.86% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 60.86%. This contributed to the annual value of $1.9 million for FY2024, which is 21.88% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Current Leases stood at $2.8 million, which was up 5.22% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Current Leases registered a high of $2.8 million during Q3 2025, and its lowest value of $1.4 million during Q1 2021.
  • In the last 3 years, Ocular Therapeutix's Current Leases had a median value of $1.8 million in 2023 and averaged $1.9 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Current Leases fell by 15.18% in 2024, and later skyrocketed by 60.86% in 2025.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Current Leases stood at $1.6 million in 2021, then dropped by 1.54% to $1.6 million in 2022, then decreased by 0.81% to $1.6 million in 2023, then climbed by 21.88% to $1.9 million in 2024, then spiked by 60.86% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $2.6 million for Q2 2025, and $2.2 million during Q1 2025.